Project Grant K08CA276999
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$235K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This Project Grant award of $225,101.00 from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), supports the creation of a comprehensive Splicing Neoantigen Atlas spanning 30 adult and pediatric cancer types. The award recipient, Childrens Hospital Medical Center in Cincinnati, Ohio, will develop an innovative computational workflow called Splicing Neoantigen Finder (SNAF) to accurately predict and experimentally validate highly shared...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $628,499 to the University of California, Los Angeles to develop innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors, with a focus on pancreatic ductal adenocarcinoma. The research framework includes mechanistic studies to optimize mRNA-encoded antigen and adjuvant properties, evaluate the new vaccines in humanized immune system mouse models,...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports a Phase I clinical trial to evaluate the safety and efficacy of CSPG4-targeted CAR-T cell therapy in adult patients with head and neck squamous cell carcinoma (HNSCC) that is refractory to platinum and PD-1 inhibitor treatment. The award of $627,456 will fund the single-center, open-label clinical trial over a 5-year period from December 2024 to November 2029....
The National Cancer Institute (NCI), part of the National Institutes of Health, awarded a $222,998 Project Grant (CFDA 93.395 Cancer Treatment Research) to the University of California, San Diego (UCSD) on March 10, 2025. The grant will fund research to engineer endogenous immune cells, including T cells, NK cells, and macrophages, to express chimeric antigen receptors (CARs) capable of targeting and killing ovarian cancer cells. The research will utilize a novel virus-like particle (VLP) vector...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $122,032 to Weill Medical College of Cornell University to conduct research on dissecting the contribution of mis-splicing in cancer phenotypes through multi-omic single-cell approaches. The key objectives are to: 1) Utilize a novel technique called GOT-SPLICE to study mutations in splicing factors and identify tumor-specific isoforms with translational potential in...
The National Cancer Institute (NCI) awarded a $619,294 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the University of California, San Diego (UCSD) to develop slow-release CPMV (Cowpea Mosaic Virus)-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to formulate CPMV-laden slow-release devices, establish and tune the release rates, confirm the structural integrity and biological activity of the released CPMV, and...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $127,629 to the President and Fellows of Harvard College's Harvard T.H. Chan School of Public Health to conduct research on the role of human leukocyte antigen (HLA) variations in cellular immunity and the efficacy of immune checkpoint inhibitor monotherapy for non-small cell lung cancer patients. The key objectives are to: 1) identify the mechanisms linking germline and somatic HLA...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $863,708 to Mirecule, Inc. to develop an antibody-oligonucleotide conjugate therapy for treating head and neck squamous cell carcinoma. The award period runs from September 18, 2024 to August 31, 2026. The key products or services to be delivered under this award include: 1) validating the efficacy of the MC-30 antibody-RNA conjugate in preclinical cancer models, 2) executing...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $563,233 to The Medical University of South Carolina to investigate strategies for overcoming immunosuppression and improving adoptive T cell therapy for cancer treatment. The key focus is on understanding how the sphingosine kinase 2 (SPHK2) and sphingosine-1-phosphate (S1P) axis regulates the suppressive function of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment....